589 related articles for article (PubMed ID: 28476042)
1. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
[TBL] [Abstract][Full Text] [Related]
2. Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.
Fang D; Zhao C; Ren D; Yu W; Wang R; Wang H; Li X; Yin W; Yu X; Yang K; Liu P; Shan G; Li S; He Q; Wang X; Xin Z; Zhou L
Ann Surg Oncol; 2016 Dec; 23(13):4284-4292. PubMed ID: 27464612
[TBL] [Abstract][Full Text] [Related]
3. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
4. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
6. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
7. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
8. Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer.
Niu XK; He WF; Zhang Y; Das SK; Li J; Xiong Y; Wang YH
Clin Radiol; 2017 Jun; 72(6):458-464. PubMed ID: 28069159
[TBL] [Abstract][Full Text] [Related]
9. Are prostate biopsies necessary for all patients 75years and older?
Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
[TBL] [Abstract][Full Text] [Related]
10. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
[TBL] [Abstract][Full Text] [Related]
11. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
12. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the performance of PI-RADS v2 in the non-academic setting.
Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
[TBL] [Abstract][Full Text] [Related]
14. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
[TBL] [Abstract][Full Text] [Related]
15. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
[No Abstract] [Full Text] [Related]
16. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
Urol Int; 2017; 99(2):177-185. PubMed ID: 28531902
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
19. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
[TBL] [Abstract][Full Text] [Related]
20. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]